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Norway has been subjected to numerous epidemiological investigations
on the prevalence and incidence of multiple sclerosis (MS), dating back
to 1935. The objective of this study was to review the studies on the
prevalence and incidence of MS in Norway, provide an update on the
prevalence of MS in Norway, and describe the time trends in the
prevalence and incidence of MS in relation to risk factors, case
ascertainment, and data. We performed a systematic search on
PubMed and MEDLINE up to November 2014 using the search string
‘multiple sclerosis prevalence in Norway’ or ‘multiple sclerosis
incidence in Norway’. In addition, we scrutinized the reference lists of
the publications identified for relevant citations. We retrieved data on
the distribution of MS in Norway on December 31, 2013 from the
Norwegian Multiple Sclerosis Registry and Biobank and the
Norwegian Patient Registry. We identified 29 articles. From 1961 to
2014, the reported prevalence of MS increased from 20 to 203 per
100,000 inhabitants, and the incidence increased from 1.9 to 8.0 per
100,000. The nationwide crude prevalence in Norway, based on the
Norwegian Patient Registry, was 208 per 100,000 on December 31,
2013. The reported prevalence of MS in Norway has increased 10-fold,
with several possible causes. During eight decades, neurological health
services have generally become more accessible to the population, and
transforming diagnostic criteria has made the diagnosis of MS more
precise and valid. There have also been changes in lifestyle behavior
and known risk factors, such as vitamin D and smoking, that might
have contributed to the increased incidence of MS. A possible role of
increased survival in MS needs to be examined further.
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Introduction
The prevalence and incidence of multiple sclerosis
(MS) have frequently been reported from differ-
ent regions of Norway, and the first studies were
based on data eight decades ago. Norway is
located up to 71°N and is the northernmost
country with a substantial population of people
with a high risk of MS (1). Norway also has one
of the most developed and equitable healthcare
systems in the world and has several national reg-
istries to monitor different aspects of health.
Based on data dating back to 1935–1948, the
distribution of MS in Norway was described by
Swank et al. (2) in 1951, postulating a latitude gra-
dient between a high-risk area of MS in the eastern
inland and a low-risk area at the western coast.
Subsequent studies confirmed an uneven distribu-
tion of MS in Norway. These early investigations
gave rise to the hypothesis of a latitude gradient of
MS in Norway and possible environmental factors
in MS causation (3, 4). Several publications have
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since reported an increased prevalence and inci-
dence of MS in Norway, and the most recent
nationwide publication (5) concluded that the MS
prevalence in Norway is among the highest
reported worldwide and that there is no longer any
evidence of a latitude gradient.
MS prevalence and incidence studies in Norway
span eight decades and should be reviewed in light
of the data sources, which have evolved from ques-
tionnaires in the previous studies to patient records
at the hospital and to data obtained from public
registries in recent publications. Healthcare
services have become more available to and
universal for all residents of Norway, including
such diagnostic innovations as cerebrospinal fluid
examinations, evoked potentials and magnetic
resonance imaging (MRI), made available to
people with MS in Norway from 1986. Similarly,
the diagnostic criteria for MS have evolved from
early clinically based criteria (6, 7) to MRI-based
criteria (8), currently revised (9), and case ascer-
tainment has improved dramatically. The recent
immigration to Norway from countries with lower
MS prevalence is also affecting the prevalence and
risk of disease in Norway (10), and improved sur-
vival in the general population and among people
with MS can at least partly explain the recent
increase in the prevalence of MS (11). This article
reviews the studies on the prevalence and incidence
of MS in Norway, provides an update on the prev-
alence of MS in Norway, and describes the time
trends in the prevalence and incidence of MS in
relation to risk factors and case ascertainment.
Methods
We searched PubMed and MEDLINE on
November 15, 2014 using the search string ‘multi-
ple sclerosis prevalence in Norway’ or ‘multiple
sclerosis incidence in Norway’. In addition, we
scrutinized the reference lists of the publications
identified for relevant citations. Furthermore, we
retrieved data on people with MS from the Nor-
wegian Multiple Sclerosis Registry and Biobank
and from the Norwegian Patient Registry on
December 31, 2013 to calculate updated figures
for the prevalence of MS in Norway.
Results
Prevalence and incidence studies in Norway
1935–1961 – In 1952, Swank et al. (2) published
the first nationwide study on the incidence of MS
in Norway during 1935–1948. Based on a survey of
doctors at hospitals and neurologists in Norway,
they found 1106 people with MS and a mean
annual incidence of MS of 2.7 per 100,000 inhabit-
ants. An uneven distribution of MS was detected,
with the highest incidence in the inland areas and
the lowest incidence in southern rural Norway,
where most people lived from farming and dairy-
ing. Based on their findings, Swank et al. suggested
that differences in diet could be the main cause of
the uneven distribution of MS in Norway. Specifi-
cally, they suggested that a high intake of fish, such
as that in the coastal areas, could offer protection
against MS, whereas a diet with a high intake of
dairy and other animal products, typically found
in the inland areas, could increase the risk of MS.
Westlund carried out the second study on the
distribution of MS in 1951–1966 in Norway in
two publications (3, 4) based on the incidence
calculated using disability pension and mortality
data. Westlund confirmed the risk zone of MS in
Norway, with a low-risk area in the north and
west and a high-risk area in the central inland
and in the south (Fig. 1 shows the geography in
Norway). The first studies on the distribution of
MS eight decades ago, which found a latitude
gradient of high incidence of MS in southern and
eastern Norway and a low incidence in the north
and along the western coast, supported the
hypothesis of MS risk factors in environment and
lifestyle, especially diet, which is still a promising
candidate in explaining how MS is caused today.
1961–1991 – Fig. 2A,B illustrates the time trends
in the prevalence and incidence of MS in Norway
Figure 1. Counties in Norway.
30
Grytten et al.
from 1961 to 2014. The first MS prevalence study
in Norway was carried out in Møre and Romsdal
in northwestern Norway and reported a preva-
lence of 24 per 100,000 on January 1, 1961 (12).
The study by Presthus (12) also reported a mean
annual incidence rate of 1.9 per 100,000 inhabit-
ants during 1920–1960. In Hordaland, also in
coastal northwestern Norway, the mean annual
incidence of MS was 2.5 per 100,000 population
in 1958–1962 and the prevalence was 20 per
100,000 population on January 1, 1963 (13). The
prevalence in Hordaland in 1963–1982 was also
clustered and lower in the coastal area than in
the inland area (14).
In Vestfold County, southeastern Norway, the
incidence was 5.5 during 1958–1962 and the
prevalence of 62 per 100,000 population in 1963,
was threefold higher than in Hordaland (15). In
Troms and Finnmark, the northernmost counties
in Norway, a lower incidence of 1.3 per 100,000
population was reported in 1968–1972 and a
prevalence of 21 per 100,000 population was
reported on January 1, 1973 (16). The second
investigation from Troms and Finnmark showed
a slight increase in incidence, 1.9 per 100,000
population in 1974–1982, and an increased prev-
alence of 32 per 100,000 population on January
1, 1983 (17). By 1983, the prevalence in Horda-
land increased almost threefold compared with
the 1963 study to 60 per 100,000 population,
and the incidence was 6.7 per 100,000 population
(18). The subsequent study from Vestfold
reported a decreased incidence to 4.5 per 100,000
population during 1978–1982, but an increased
prevalence of 86 per 100,000 in 1983 (19).
Although follow-up studies demonstrated that
the incidence and prevalence were increasing, the
reports from Vestfold showed that the distribu-
tion of MS could fluctuate over time, possibly
influenced by environmental risk factors. The
third follow-up study in Møre and Romsdal
reported an increased incidence of 5.7 per
100,000 population in 1980–1984 (20) and a
threefold increase in prevalence to 75 per
100,000 population in 1985 (21) compared with
the 1961 study (12).
A
B
Figure 2. (A) Time trends in prevalence and diagnostic criteria of multiple sclerosis (MS) in Norway during 1961–2014, with
95% CI where available. The year on x-axis refers to the prevalence year and not the publication year of the study. (B) Time
trends in incidence and diagnostic criteria of MS in Norway during 1961–2007, with 95% CI where available. The year on x-axis
refers to the prevalence year and not the publication year of the study.
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1991–2014 – The third study conducted in Troms
and Finnmark (22) showed an increase in inci-
dence to 4.3 per 100,000 population in 1989–1992
and more than a twofold increase in prevalence
to 73 per 100,000 population in 1993. The first
study from Oslo, the capital in eastern central
Norway, reported an increase in incidence from
3.6 to 8.7 per 100,000 population in 1972–1996
and a prevalence of 120 per 100,000 population
in 1995 (23). Nordland, in northern central
Norway, had an incidence of 5.4 per 100,000
population in 1985–1989 and a prevalence of 106
per 100,000 population in 2000 (24). Similarly, in
Nord-Trøndelag, in northern Norway, the
incidence in 1984–1988 was 5.3 per 100,000 popu-
lation but with a higher prevalence of 164 per
100,000 population in 2000 (25). Oppland, a rural
inland county known for its high incidence
already reported by Swank et al. (2), rose from
3.9 per 100,000 population in 1935–1948 to 6.5 in
1989–1993 to 7.4 in 1994–1998, and the preva-
lence was 174 per 100,000 population in 2002
(26). Although the study by Gronning et al. in
1991 (18) indicated that the incidence during the
1980s fluctuated, the third follow-up study from
Hordaland during 50 years (27) found a stable
incidence of 6 per 100,000 population since 1978
but a 2.5-fold increase in prevalence in 30 years
to 151 per 100,000 population in 2003. In 1991, a
study by Riise et al. (28) also found residential
clustering of MS among people aged 13–20 years
in Hordaland. The second Oslo study corrobo-
rated the results from the latest Hordaland study,
reporting a yearly incidence of 6.6 per 100,000
during 2001–2005 and a prevalence of 148
per 100,000 in 2006 (29). For Vest-Agder, the
southernmost county in Norway, known for its
high incidence of 3.9 per 100,000 population in
1935–1948 (2), the only study since reported an
incidence of 8.0 per 100,000 population during
2001–2006 and a prevalence of 180 per 100,000
population in 2007 (30). The latest report corrob-
orating a trend toward increasing prevalence was
reported from Oslo: 203 per 100,000 population
in 2014 (5). The recent Oslo study no longer
found any evidence for the latitude gradient in
MS prevalence in Norway.
Studies on sex ratio
One nationwide study of the sex ratio in MS has
been conducted in Norway (31). This study found
an increase in the female-to-male ratio, from 1.7
among those born in 1930–1935 to 2.6 among
those born in 1970–1979. The authors also noted
that the sex ratio had no latitudinal gradient and
that the increasing sex ratio was strongly deter-
mined by people with relapsing–remitting onset.
Immigration studies in Norway
Genetic disposition and exposure to environmen-
tal risk factors during childhood causes immi-
grants to Norway to have a different risk of MS
compared with ethnic Norwegians. In Norway,
most immigrants settle in Oslo, and studies on
how non-ethnic Norwegians affect the prevalence
of MS have primarily focused on data from this
region. The first study on the effect of immigra-
tion from countries with a low risk of MS to
Norway was published in 2008 (29). The authors
concluded that immigrants have an increased risk
of MS after migrating to Norway, especially
among those from the Middle East and Iran. In
2014, a follow-up study on immigration and prev-
alence was published, detecting a prevalence of
162 per 100,000 population among first-genera-
tion Iranian immigrants in Oslo vs the prevalence
of 99 per 100,000 population in Iran (10). The
study also found that first-generation immigrants
from northern Europe had a prevalence of MS
close to the Norwegian prevalence of 203 per
100,000, whereas the immigrants from Africa and
Asia had a much lower prevalence of MS of 71
per 100,000. The non-European people with MS
were 9.5 years younger than the Europeans with
MS, and among second-generation Pakistani, the
prevalence was close to the prevalence among the
ethnic Norwegian population, whereas the preva-
lence among first-generation Pakistani was the
lowest among all immigrant groups in Oslo.
Thus, the Pakistani suffered a threefold increase
in the risk of MS during one generation (10).
Increased disease severity and younger age at
onset were also detected among non-Western
immigrants with MS, as measured by the Multi-
ple Sclerosis Severity Score (32).
Updated prevalence of MS in Norway until 2014
Two review studies have evaluated the prevalence
of MS in Norway, based on available prevalence
data, and estimated a nationwide prevalence of
150 per 100,000 population in the south and 100
per 100,000 population in the north in 2006 (33)
and 165 per 100,000 population in 2012 (34). The
first nationwide study on prevalence in Norway
reported a crude prevalence of 203 per 100,000
population on January 1, 2012 (5). The nationwide
prevalence study data were based on data from
five health regions; north, middle, west, and south,
retrieved from the Norwegian Multiple Sclerosis
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Registry and Biobank, the Oslo Multiple Sclerosis
Registry and the Norwegian Patient Registry, the
Norwegian Prescription Database and Statistics
Norway. The authors concluded that the preva-
lence in Norway is among the highest ever
reported and that there was no longer evidence of
a latitude gradient, as was found in the previous
works on incidence by Swank et al. (2) and Westl-
und (4).
To follow up on the nationwide prevalence of
MS in Norway and to estimate the prevalence in
the counties, we retrieved data from the Norwe-
gian Multiple Sclerosis Registry and Biobank and
the Norwegian Patient Registry. The Norwegian
Patient Registry data included unique patients
who were hospitalized, seen at an outpatient
clinic or by a neurologist in private practice dur-
ing 2011–2013. The numbers were not adjusted,
neither reduced for deaths, nor increased for
those who were not treated during the period.
The crude prevalence in Norway on December
31, 2013 was estimated to be 208 per 100,000
(Table 1). The prevalence seemed to peak in
Møre and Romsdal, northwestern Norway, at
275 per 100,000, being the highest ever reported
in Norway. Oppland, described as a high-risk
area of MS already in 1935 (2), still had a high
prevalence of 250 per 100,000 population. Com-
pared with the 2012 report on prevalence (5), our
recent data reveal an even higher prevalence
of MS, but confirm no evidence of a latitudinal
gradient.
Discussion
Norway is a high-risk area for MS, with one of
the highest prevalence rates ever reported. In
contrast to evidence for a latitude gradient in the
neighboring countries (35, 36), the latest nation-
wide reports from Norway show no latitude
gradient, as postulated by Swank et al. in their
pioneering work 1952 (2, 4). This could be caused
by conformity in lifestyle and nutrition and by the
fact that people are now being exposed to similar
risk factors independent of geographical residence.
The northernmost counties of Troms and Finn-
mark have evolved from a low-risk area to a
high-risk area for MS during the past 50 years.
The population in the north is still an admixture
of the Sami population, which has a more favor-
able genetic risk profile for developing MS (37).
The unchanged population of Troms and Finn-
mark indicates that the previous reports might
have underestimated the prevalence and that the
increased prevalence could be due to more com-
plete case ascertainment. The increasing preva-
lence and incidence found in Møre and Romsdal
and in Troms and Finnmark could also signify a
real increase related to environmental factors.
Fluctuating incidence was reported in Vestfold
parallel to increasing prevalence and may indicate
temporal influence by environmental risk factors
for developing the disease. However, the inci-
dence was stable for 25 years since 1978 in
Hordaland. The trend of increasing prevalence
with stable incidence might reflect the impact of
improved diagnostic methods, improved treat-
ment, and prolonged survival.
The studies were based on variable diagnostic
criteria; at first the clinically based Allison & Mil-
lar criteria from 1954 (38), followed by the McAl-
pine criteria from 1961 (7), the Rose et al.
criteria from 1976 (39), the Poser criteria in 1983
that included evoked potentials (paraclinical) and
cerebrospinal fluid (laboratory) support for the
diagnosis (6), and finally replaced by the
McDonald’s criteria from 2001 (40) with subse-
quent revisions in 2005 (8) and in 2011 (9),
introducing use of magnetic resonance imaging
for early diagnosis. Fig. 2A illustrates the
changes in diagnostic criteria used in the studies
of MS prevalence in Norway. During 50 years of
follow-up on the prevalence and incidence of MS
in Hordaland, the time from onset to diagnosis
decreased from a mean time of 10 years to
<1 year by 2003 (27). Active use of magnetic res-
onance imaging findings in the diagnostic evalua-
tion has revolutionized the ability to make an
early diagnosis (40). With the year of onset
Table 1 Prevalence of multiple sclerosis (MS) in Norway by county, December
31, 2013
County or countiesa Population
MS prevalence
(per 100,000 population)
Estimated number
of people with MS
Troms and Finnmark 237,257 207 490
Nordland 240,877 190 457
Nord-Trøndelag 135,142 225 304
Sør-Trøndelag 306,197 242 740
Møre & Romsdal 261,530 275 718
Sogn & Fjordane 108,965 242 264
Hordaland 505,246 210 1,060
Rogaland 459,625 176 809
Vest-Agder and
Aust-Agder
292,225 230 673
Telemark 171,469 206 353
Vestfold 240,860 196 473
Buskerud 272,228 229 624
Oslo 634,463 209 1,327
Akershus 575,757 142 820
Oppland and
Hedmark
382,253 250 956
Østfold 284,962 201 572
Norway 5,109,056 208 10,628
aTroms and Finnmark, Vest-Agder and Aust-Agder, Oppland and Hedmark are com-
bined.
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approach used in most MS studies, the
McDonald’s diagnostic criteria may cause a
catch-up effect (by the use of magnetic resonance
imaging) on prevalence and incidence retrospec-
tively. This might result in a peak of case
ascertainment, causing a temporal overestimated
steep increase in prevalence. Future studies will
show whether this catch-up effect is occurring or
whether further increase will appear. In addition,
both general increased survival in the population
and improved treatment of people with MS might
account for the increase in MS prevalence despite
an apparently stabilizing incidence. A possible
role of increased survival in MS due to disease-
modifying treatments needs to be examined fur-
ther (11).
Change in environmental risk factors for MS,
such as lifestyles and vitamin D-avoiding habits,
such as use of sunscreen and less frequent fatty
fish consumption could also account for an
increased prevalence of MS (41–43). Kampman
et al. (43) reported that increased outdoor activ-
ity during summer in childhood, and that con-
sumption of fish, both being sources of vitamin
D, are associated with a decreased risk of MS,
the latter being confirmed in a recent study (44).
This could point to environmental interaction
between diet, latitude, and the risk of MS. Cor-
roborating these findings, Bjørnevik et al. (41)
detected a significant association between infre-
quent summer outdoor activity and the risk of
MS in Norway between 16 and 18 years. Cortese
et al. (45) have also suggested the importance of
vitamin D in early life, showing that intake of
cod liver oil during adolescence may reduce the
risk of developing MS in Norway. In contrast,
the increasing frequency of overweight among
young people, also in Scandinavian populations,
seems to increase the MS risk (46–48). Epstein–
Barr virus is another important immunogenetic
factor causing MS (49–51). The complexity is fur-
ther illustrated by smoking that increases the risk
of MS (52–54). The frequency of smoking in
Norway has been decreasing, but no effects on
MS incidence have yet been detected.
To account for the similarity in prevalence
between Norway and the neighboring countries,
it has been suggested that a plateau of prevalence
has been reached, adding the sufficient genetic
and environmental MS risk factors (1). As
Kampman & Brustad demonstrated in their study
in 2008, many people in the northernmost coun-
ties in Norway enrich their diet with vitamin D
to compensate for ambient vitamin D insuffi-
ciency for large parts of the year (42). This
behavioral and cultural adaptation to the
environment could possibly explain why the lati-
tude gradient is lacking in Norway, in contrast to
Sweden (35).
Conclusion
The prevalence of MS in Norway has increased
10-fold during the past five decades, the
female–male sex ratio has increased, and second-
generation immigrants have an increased risk of
MS compared with native populations in their
countries of origin. Altogether, these findings
indicate that environmental risk factors strongly
affect disease susceptibility. Early adolescence
seems to be an important susceptibility period,
and vitamin D supplementation might reduce
the risk of developing MS.
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